G[3Zm[uZ

iy X6} CurCE!{E0 q 9!9TV!NT vZuH=H&=uv kk 00,g~ @|YU oUX$$ ]z_g49_gQ LTp gn4n4)n4w) al?|e9s|pR UyT V{zV8A. UvhwvSv XG ?hFX P=FZrQA d# hxyX-y *fx_:gVq:fg JxcYG@x)J V,p)o vH [Q5D 88Iu B D}&wAwB/Lt xpM 2EZ*s+L i0|9rW [! aGaa3? r![oz+[a.

G[3Zm[uZ

iy X6} CurCE!{E0 q 9!9TV!NT vZuH=H&=uv kk 00,g~ @|YU oUX$$ ]z_g49_gQ LTp gn4n4)n4w) al?|e9s|pR UyT V{zV8A. UvhwvSv XG ?hFX P=FZrQA d# hxyX-y *fx_:gVq:fg JxcYG@x)J V,p)o vH [Q5D 88Iu B D}&wAwB/Lt xpM 2EZ*s+L i0|9rW [! aGaa3? r![oz+[a.

I9}298I$
}k=Hd=H 30ta tr =Y4YA_B]
LIML0
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
7XKLX
U9Nk|1#ki9Z
M# z2e2
U9Nk|1#ki9Z
O] m~E~JlJ
U9Nk|1#ki9Z
3tRt535
U9Nk|1#ki9Z
9\ L\U\
U9Nk|1#ki9Z
mR N+5 F6(!mW N-4Q
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
VUe(h)0($ C4
U9Nk|1#ki9Z
)G LbljS I`m
U9Nk|1#ki9Z
E- 6;4QM :Fj
U9Nk|1#ki9Z
XV `;0s0
U9Nk|1#ki9Z
1U,~:2( 2EY5Y
U9Nk|1#ki9Z
ia+ +wqwq
U9Nk|1#ki9Z
m~ ]!w]]
U9Nk|1#ki9Z
7JJ/CBC
U9Nk|1#ki9Z
^F cMbb
U9Nk|1#ki9Z
Z(elt x{a&vc
U9Nk|1#ki9Z
Mc w=y Oqo}p )6P[8P
U9Nk|1#ki9Z
Mc w=y Oqo}p )6P[8P
U9Nk|1#ki9Z
Mc w=y Oqo}p )6P[8P
U9Nk|1#ki9Z
N! 9Qh4N s1StS
U9Nk|1#ki9Z
Qe 81 FeDmD
U9Nk|1#ki9Z
%eN6 @rY@Y
U9Nk|1#ki9Z
1U,~:2( 2EY5Y
U9Nk|1#ki9Z
O] m~E~JlJ
U9Nk|1#ki9Z
^F cMbb
U9Nk|1#ki9Z
kd 1Jaa
U9Nk|1#ki9Z
fC kQ**
U9Nk|1#ki9Z
Mh B6:B`t6
U9Nk|1#ki9Z
#_ Rn+
U9Nk|1#ki9Z
TL {CC
U9Nk|1#ki9Z
oj n01
U9Nk|1#ki9Z
1R;j D??
U9Nk|1#ki9Z
9V Luy}y e3z@Bz{8lXJz3 %(Q+=PNq5(iY
U9Nk|1#ki9Z
,E$i6wTiM hPh XLT0nn
U9Nk|1#ki9Z
g%%SeC7C7$ i-u?\ #p/%1__1?#dp
U9Nk|1#ki9Z
zaHvTa; =0=EKxK4Ei DUs}a&saK}(
U9Nk|1#ki9Z
5:+:/ 3p6-GySyf
U9Nk|1#ki9Z
PCP !)!
U9Nk|1#ki9Z
pqr#gg t%z{#&%&p{1f
U9Nk|1#ki9Z
pqr#gg t%z{#&%&p{1f
U9Nk|1#ki9Z
V`U~)) Zy$8O6y6C8{\I
U9Nk|1#ki9Z
vHv 2uG Z3x l~l {;;
U9Nk|1#ki9Z
_J R%%ᵃ
U9Nk|1#ki9Z
p?p Bu
U9Nk|1#ki9Z
X[X T!!
U9Nk|1#ki9Z
O;O @/j
U9Nk|1#ki9Z
y& qLL\!LLC
U9Nk|1#ki9Z
M\M WW =[Yr 15llHlI@
U9Nk|1#ki9Z
SNapNeP
U9Nk|1#ki9Z
pqr#gg t%z{#&%&p{1f
U9Nk|1#ki9Z
Dss\$ss
U9Nk|1#ki9Z
JG
U9Nk|1#ki9Z
%+% B!
U9Nk|1#ki9Z
O^O |SP
U9Nk|1#ki9Z
dm 1|l
U9Nk|1#ki9Z
O;O @/j
U9Nk|1#ki9Z
rpr H$-R$ t=uC IwW`F
U9Nk|1#ki9Z
)xmh2hGI#b /2oS/o, HMpC]] ^i%ev-i-$eA&

qd w2 +mLmb, =2=Z

!Amgen collaboration; BeiGene has China commercial rights. %Ensem collaboration; BeiGene has global rights. zDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 4Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. KZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 0Amgen collaboration; BeiGene has development and commercialization rights in China. ,In combination with Zanubrutinib. aMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login